首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

2075128

嗜伊紅性食道炎市場：按藥物類別、分銷管道和地區分類的規模、佔有率、前景和機會分析（2025-2032 年）

Eosinophilic Esophagitis Market, by Drug Class, by Distribution Channel, and by Region Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

嗜伊紅性食道炎市場預計在 2026 年達到 3.194 億美元，預計到 2033 年將達到 24.268 億美元。預計從 2026 年到 2033 年，該市場將以 33.6% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	3.194億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	33.60%	2033年市場規模預測：	24.268億美元

嗜伊紅性食道炎是一種慢性疾病，治療方法包括使用抑酸質子幫浦阻斷劑。類固醇有助於抑制發炎。局部固醇可經由吸入劑或液體給藥。對於有嚴重吞嚥困難或體重減輕的患者，醫生可能會開立口服類固醇。質子幫浦阻斷劑有助於緩解逆流症狀並減輕發炎。

市場動態

人們對嗜伊紅性食道炎)的認知不斷提高，推動了治療需求的成長。因此，主要市場參與者正致力於開發新的療法以滿足此需求。例如，全球生物製藥公司賽諾菲正在進行 Dupixent（度普利尤單抗）的 III 期臨床試驗，預計將於 2024 年完成。此外，能夠改善 EoE 治療的創新產品的出現有望推動全球市場成長。例如，2021 年 12 月，日本跨國製藥公司武田藥品工業株式會社接受了美國食品藥物管理局(FDA) 針對 TAK-721（Budesonide口服懸浮液，一種用於治療嗜伊紅性食道炎的藥物）的完整回覆函 (CRL)。 2021 年 6 月，美國 FDA 授予 etrasimod 孤兒藥資格認定 (ODD)，該藥物由美國生物製藥公司 Arena Pharmaceuticals 研發。此外，嗜伊紅性食道炎盛行率的上升也可能促進市場成長。例如，2018年7月發表在《沙烏地醫學日誌》上的一項研究發現，嗜伊紅性食道炎是一種新興疾病，在沙烏地阿拉伯兒童的發生率不斷上升。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球嗜伊紅性食道炎市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球嗜伊紅性食道炎市場」報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用全球嗜伊紅性食道炎分析中使用的各種策略矩陣來簡化決策過程。

皮質類固醇
質子幫浦阻斷劑（PPI）
- 介紹
- 市場規模及預測、年增速分析
  - 奧美拉唑
  - Esomeprazole
  - 其他
後期研發管線藥物
- 介紹
- 市場規模及預測、年增速分析
  - 杜皮森特
  - APT-1012
  - 瑞倫特利單抗（AK002）
  - Cendakimab
  - 埃特拉西莫多
  - TAK-721
  - 奧米蘭科爾（BT-11）

第5章全球嗜伊紅性食道炎市場：依通路分類，2021-2033年

醫院藥房
零售藥房
網路藥房

第6章全球嗜伊紅性食道炎市場：依地區分類，2021-2033年

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
- Ellodi Pharmaceuticals.
- EsoCap AG
- GlaxoSmithKline plc.
- Teva Pharmaceutical Industries Ltd
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi SA
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Falk Pharma GmbH

第8章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第9章

參考
調查方法

簡介目錄

Product Code: CMI4909

Eosinophilic Esophagitis Market is estimated to be valued at USD 319.4 Mn in 2026 and is expected to reach USD 2,426.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 33.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 319.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	33.60%	2033 Value Projection:	USD 2,426.8 Mn

Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.

Market Dynamics

Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2024. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eosinophilic esophagitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis

Detailed Segmentation:

Global Eosinophilic Esophagitis Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Corticosteroids
- Budesonide
  - Jorveza
  - Off-label budesonide
- Fluticasone
Proton Pump Inhibitor (PPI)
- Omeprazole
- Esomeprazole
- Others
Late Stage Pipeline Drugs
- Dupixent
- APT-1011
- Lirentelimab (AK002)
- Cendakimab
- Etrasimod
- TAK-721
- Omilancor (BT-11)
Global Eosinophilic Esophagitis Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Eosinophilic Esophagitis Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country
  - U.S.
  - Canada
Latin America
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Country/Region
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
GlaxoSmithKline plc*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
Ellodi Pharmaceuticals
EsoCap AG
Teva Pharmaceutical Industries Ltd.
Cipla Limited
Sun Pharmaceutical Industries Limited
AstraZeneca Plc
Sanofi S.A.
Arena Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Revolo Biotherapeutics
Allakos Inc.
Bristol-Myers Squibb Co
Calypso Biotech
DBV Technologies
Landos Biopharma, Inc.
Glenmark Pharmaceuticals
Alkem Laboratories Ltd.
Quorum Innovations LLC
Dr. Falk Pharma GmbH

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Recent Product Approval/Launch
PEST Analysis
Epidemiology

4. Global Eosinophilic Esophagitis Market, By Drug Class, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
  - Budesonide
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
      - Jorveza
        
        Introduction
        Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
      - Off-label budesonide
        
        Introduction
        Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
  - Fluticasone
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
Proton Pump Inhibitor (PPI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
  - Omeprazole
  - Esomeprazole
  - Others
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
  - Dupixent
  - APT-1012
  - Lirentelimab (AK002)
  - Cendakimab
  - Etrasimod
  - TAK-721
  - Omilancor (BT-11)

5. Global Eosinophilic Esophagitis Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

6. Global Eosinophilic Esophagitis Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2029 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Ellodi Pharmaceuticals.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- EsoCap AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- GlaxoSmithKline plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Cipla Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sun Pharmaceutical Industries Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca Plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sanofi S.A.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Arena Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- Takeda Pharmaceutical Company Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- Revolo Biotherapeutics
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- Allakos Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- Bristol-Myers Squibb Co
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- Calypso Biotech
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- DBV Technologies
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- Landos Biopharma, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- Glenmark Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Alkem Laboratories Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Quorum Innovations LLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- Falk Pharma GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies

8. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

9. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

嗜伊紅性食道炎治療市場：策略性洞察與預測（2026-2031 年）

嗜伊紅性食道炎（EoE）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

嗜伊紅性食道炎市場：商業機會、成長要素、產業趨勢分析及2026-2035年預測

嗜伊紅性食道炎（EoE）：新型療法、未滿足的需求和目標產品展望報告，2026 年

嗜伊紅性食道炎（EoE）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

FAQ

嗜伊紅性食道炎市場：按藥物類別、分銷管道和地區分類的規模、佔有率、前景和機會分析（2025-2032 年）